A Clinical Study of Different Administration of Pamidronate in the Patients with Painful Bone Metastases Due to Lung Cancer

CHEN Ying-xia,QIN Shu-kui,SHI Yi,QIAN Jun,WANG Lin,HE Ze-ming

DOI: https://doi.org/10.3969/j.issn.1008-8199.2005.06.013

2005-01-01

Abstract:Objective: To compare the efficacy and safety of different administration of pamidronate for relieving bone pain and to improve the living quality in Chinese patients with painful bone metastases due to lung cancer. Methods:96 patients with painful bone metastases due to lung cancer were randomly enrolled to group A (150 mg) or group B (90 mg). There were 53 patients receiving 150 mg of pamidronate(34 pts for 2 days and 19 patients for 5 days administration). 43 (patients) receiving 90 mg of pamidronate. Results:There were 84.9% of patients relieving bone pain in group A and (67.4%) in group B (P=0.043). The score measuring bone pain decreased from 6.47±1.45 to (3.28±)1.71 in group A and from 6.21±1.49 to 3.49±2.88 in group B after injection of pamidronate , and the mean duration for pain relief were 28.00 days and 21.00 days respectively(P0.001). There were more patients in group A whose antalgica effects decreased or downgraded than in group B (34.8% vs 13.5%,(P=)(0.027)). There were no differences of the percentages of patients with improvement of activity ability and KPS between the two groups. QOL were improved after the treatment in two groups, and the degree of improvement was higher in the patients in group A .The main side effect of pamidronate was fever , and there was no difference between group A and B. Conclusion: Pamidronate can relieve pain due to bone metastasis from lung cancer and improve the living quality. 150 mg of pamidronate is better than 90 mg of pamidronate in efficacy. The side-effects in two groups were the same.